Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer

Related Videos

Related Content

Advertisement

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

July 22nd 2025

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

AJMC Staff

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.

Related Content

Advertisement

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

July 22nd 2025

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

AJMC Staff

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.